Huseyin Naci associate professor of health policy, Aaron S Kesselheim professor of medicine, John-Arne Røttingen chief executive, Georgia Salanti associate professor of biostatistics and epidemiology, Per O Vandvik professor of medicine, Andrea Cipriani professor of psychiatry et al
Naci H, Kesselheim A S, Røttingen J, Salanti G, Vandvik P O, Cipriani A et al.
Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19
BMJ 2020; 371 :m3869
doi:10.1136/bmj.m3869
Re: Producing and using timely comparative evidence on drugs: and neglecting a hormone
When I read lists of acronymic institutions from WHO downwards all chasing the same narrow range of drugs I despair.
In March I raised, in a BMJ Rapid Resonse, the possiblty of a simple, cheap, available and safe intervention. It is not a drug and I have been supplementing with 4000 IU pd as have most of my family, friends, and aquaintances.
Clearly those in acronymic institutions never read BMJ RRs or they would have read many subsequent responses supporting the efficacy of this hormone against COVID-19: preventive 4000 IU pd; oral bolus upon infection, and high dose upon hospital admission. Eventually a nation is going to implement supplementation for all its population and thereby safely exit COVID-19. WHO, NICE, Wellcome-Gates, and fellow acronymics will be found to have been lethally blinkered.
If - by remote chance - one of their staff read this RR, Google Scholar has over 1000 hits for the string: " COVID-19 + 25(OH)D ". At the very least those running trials of drugs for C-19 need to take into account that solar D3 boosts our immune systems, in northern nations, from spring until December. Any drug trial that fails to embrace that is fundamentally flawed. The much lower case fatality rate measured now is likely due as much to summer sunshine as to enhanced ICU procedures.
Competing interests: No competing interests